Nina Wagner-Johnston

Associate Professor

If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Nina Wagner-Johnston is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles
Lymphoma Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
Mantle-Cell Lymphoma Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Hodgkin Disease Medicine & Life Sciences
Follicular Lymphoma Medicine & Life Sciences
Cyclophosphamide Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1999 2019

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., Brown, J., Chanan-Khan, A. A., Chavez, J. C., Coutre, S. E., Davis, R. S., Fletcher, C. D., Hill, B., Kahl, B. S., Kamdar, M., Kaplan, L. D., Khan, N., Kipps, T. J., Ma, S., Malek, S. & 9 others, Mato, A., Mosse, C., Neppalli, V. T., Shadman, M., Siddiqi, T., Stephens, D., Wagner-Johnston, N., Dwyer, M. A. & Sundar, H., Jan 1 2019, In : JNCCN Journal of the National Comprehensive Cancer Network. 17, 1, p. 12-20 9 p.

Research output: Contribution to journalArticle

B-Cell Chronic Lymphocytic Leukemia
Lymphoma, Large B-Cell, Diffuse
Hodgkin Disease

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL (Oncotarget(2018) 9 (13023 -13035) DOI: 10.18632/oncotarget.24310)

Byrd, J. C., Smith, S., Wagner-Johnston, N., Sharman, J., Chen, A. I., Advani, R., Augustson, B., Marlton, P., Renee Commerford, S., Okrah, K., Liu, L., Murray, E., Penuel, E., Ward, A. F. & Flinn, I. W., Jan 1 2019, In : Oncotarget. 10, 38, p. 3827-3830 4 p.

Research output: Contribution to journalComment/debate

Open Access

DYNAMO: A Phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma

Flinn, I. W., Miller, C. B., Ardeshna, K. M., Tetreault, S., Assouline, S. E., Mayer, J., Merli, M., Lunin, S. D., Pettitt, A. R., Nagy, Z., Tournilhac, O., Abou-Nassar, K. E., Crump, M., Jacobsen, E. D., De Vos, S., Kelly, V. M., Shi, W., Steelman, L., Le, N. D., Weaver, D. T. & 3 others, Lustgarten, S., Wagner-Johnston, N. & Zinzani, P. L., Jan 1 2019, In : Journal of Clinical Oncology. 37, 11, p. 912-922 11 p.

Research output: Contribution to journalArticle

Open Access
Non-Hodgkin's Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Follicular Lymphoma

Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study

Hamlin, P. A., Flinn, I. W., Wagner-Johnston, N., Burger, J. A., Coffey, G. P., Conley, P. B., Michelson, G., Leeds, J. M., Der, K., Kim, Y., Sabalvaro-Torres, A., Birrell, M., Pandey, A., Curnutte, J. T. & Patel, M. R., Jan 1 2019, (Accepted/In press) In : American Journal of Hematology.

Research output: Contribution to journalArticle